舌下含服黄体酮含片是程序化冻融胚胎移植周期中肌内注射油剂黄体酮的可行替代方案
这项回顾性队列研究纳入2018年1月至2023年4月间1951个程序化冻融胚胎移植周期,比较舌下含服黄体酮含片与肌内注射油剂黄体酮的妊娠结局和血清黄体酮水平。调整混杂因素后,两组临床妊娠、持续妊娠、活产和流产率均无显著差异;肌内注射组在胚胎移植时和首次妊娠试验时血清黄体酮水平显著更高。作者认为舌下含服黄体酮是可行替代方案,可减少注射负担且可能提高患者满意度。
要点
- 舌下含服与肌内注射黄体酮组临床妊娠、持续妊娠、活产和流产率均无显著差异。
- 肌内注射组胚胎移植时和首次hCG检测时血清黄体酮水平显著高于舌下含服组。
- 作者认为舌下含服黄体酮是程序化冻融胚胎移植周期的可行替代方案,可减少注射负担。
核心结论
- 舌下含服黄体酮是程序化冻融胚胎移植周期中肌内注射黄体酮的可行替代方案,可减少注射负担并可能提高患者满意度,且不损害妊娠结局。
- 舌下含服途径的黄体酮水平虽略低于肌内注射途径,但处于黄体支持的 acceptable 范围内。
研究设计与样本
- 回顾性队列研究,纳入2018年1月至2023年4月间所有接受单个整倍体优质囊胚程序化冻融胚胎移植的患者。
- 共纳入1951个程序化冻融胚胎移植周期,其中1030例(52.8%)接受肌内注射黄体酮,921例(47.2%)接受舌下含服黄体酮。
- 暴露因素:舌下含服含200 mg微粒化黄体酮的复方含片每日三次,或肌内注射油剂黄体酮50 mg每日一次;两组均同时使用阴道微粒化黄体酮100 mg每日三次。
主要发现
- 调整年龄、种族、雌激素准备方案、子宫内膜厚度、移植医生和既往胚胎移植次数后,肌内注射组与舌下含服组的临床妊娠率分别为69.5%与74.4%(OR 0.81,95%CI 0.61-1.09),无显著差异。
- 肌内注射组与舌下含服组的持续妊娠率分别为56.1%与61.1%(OR 0.78,95%CI 0.60-1.01),无显著差异。
- 肌内注射组与舌下含服组的活产率分别为50.1%与57.0%(OR 0.85,95%CI 0.64-1.14),无显著差异。
- 肌内注射组与舌下含服组的流产率分别为25.1%与24.1%(OR 1.24,95%CI 0.87-1.79),无显著差异。
- 肌内注射组在胚胎移植时的平均血清黄体酮水平显著高于舌下含服组(41.6 ± 10.9 vs. 30.5 ± 15.7 ng/mL),在首次血清hCG检测时也显著更高(36.5 ± 11.5 vs. 29.4 ± 15.0 ng/mL)。
临床怎么用
- 作者认为舌下含服黄体酮可作为程序化冻融胚胎移植周期中肌内注射黄体酮的可行替代方案,以减少注射负担并可能提高患者满意度。
- 作者指出舌下含服途径的黄体酮水平虽略低于肌内注射途径,但处于黄体支持的 acceptable 范围内。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare pregnancy outcomes and serum progesterone levels between women who took sublingual (SL) progesterone lozenges vs. intramuscular (IM) administration progesterone-in-oil for endometrial preparation and luteal support in programmed frozen embryo transfer (pFET) cycles. DESIGN: Retrospective cohort study. SUBJECTS: All patients who underwent pFET of a single euploid good-quality blastocyst between January 2018 and April 2023. EXPOSURE: Patients received either compounded SL lozenges containing 200 mg micronized progesterone three times per day or 50 mg progesterone-in-oil daily. Both groups also took 100 mg vaginal micronized progesterone three times per day. MAIN OUTCOME MEASURES: Primary outcomes included clinical pregnancy (human chorionic gonadotropin ≥ 5 mIU/mL), ongoing pregnancy (pregnancy progressing past 8 weeks), live birth, and miscarriage. Secondary outcomes included progesterone levels at or one day before embryo transfer and at the time of the first pregnancy test. RESULTS: A total of 1,951 pFET cycles were included, of whom 1,030 (52.8%) patients received IM progesterone and 921 (47.2%)-SL progesterone. There were no significant differences between the IM and SL groups, respectively, in clinical pregnancy (69.5% vs. 74.4%, odds ratio [OR]: 0.81, 95% confidence interval [CI]: 0.61-1.09), ongoing pregnancy (56.1% vs. 61.1%, OR: 0.78, 95% CI: 0.60-1.01), live birth (50.1% vs. 57.0%, OR: 0.85, 95% CI: 0.64-1.14), or miscarriage (25.1% vs. 24.1%, OR: 1.24, 95% CI: 0.87-1.79) after controlling for age, race, estrogen preparation, endometrial thickness, physician performing the transfer, and number of prior embryo transfers. In the IM progesterone group, mean serum progesterone levels were significantly higher at the time of embryo transfer (41.6 ± 10.9 vs. 30.5 ± 15.7 ng/mL) and at first serum human chorionic gonadotropin measurement (36.5 ± 11.5 vs. 29.4 ± 15.0 ng/mL) compared with the SL group. CONCLUSION: Sublingual progesterone is a viable alternative to IM progesterone for pFET cycles that can minimize injection burden and likely improve patient satisfaction without compromising pregnancy outcomes. Progesterone levels, although slightly lower than the IM route, are in an acceptable range for luteal support.
引用
- Mandelbaum RS, Raj-Derouin N, Erickson K, et al. Sublingual progesterone lozenges are a viable alternative to intramuscular progesterone-in-oil for programmed frozen embryo transfer cycles. Fertil Steril. 2025. PMID: 39848422. doi:10.1016/j.fertnstert.2025.01.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。